Clinical Trial Update: Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing amcenestrant to tamoxifen in hormone receptor-positive early breast cancer patients who discontinued aromatase inhibitors due to toxic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Amcenestrant (SAR439859)
• Tamoxifen (tamoxifen)

Snippet

Sponsor: Sanofi | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2023-06-22